Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a $10.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com upgraded Lexicon Pharmaceuticals to a sell rating in a report on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Lexicon Pharmaceuticals presently has an average rating of Hold and an average price target of $7.50.

Lexicon Pharmaceuticals Stock Down 1.9 %

Shares of NASDAQ:LXRX opened at $1.57 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 11.51 and a quick ratio of 11.49. The stock has a market cap of $386.59 million, a price-to-earnings ratio of -1.89 and a beta of 1.33. The company has a 50 day moving average of $1.75 and a 200-day moving average of $1.83. Lexicon Pharmaceuticals has a one year low of $0.92 and a one year high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. The firm had revenue of $1.65 million during the quarter, compared to analyst estimates of $2.74 million. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. During the same quarter in the previous year, the business earned ($0.22) EPS. On average, sell-side analysts forecast that Lexicon Pharmaceuticals will post -0.69 earnings per share for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Cantor Fitzgerald L. P. bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $25,000. CVI Holdings LLC bought a new stake in shares of Lexicon Pharmaceuticals in the second quarter worth about $34,000. Principal Financial Group Inc. raised its position in shares of Lexicon Pharmaceuticals by 116.1% during the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 12,225 shares during the period. Great Point Partners LLC bought a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $50,000. Finally, Victory Capital Management Inc. lifted its holdings in shares of Lexicon Pharmaceuticals by 44.5% during the 2nd quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 13,972 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.